Raynaud's Phenomenon

Also known as: Raynaud Phenomena / Raynaud’s phenomenon / Raynaud Phenomenon / Raynaud's syndrome / Raynaud's syndrome NOS / Raynauds' phen / Raynaud's disease

DrugDrug NameDrug Description
DB00770AlprostadilAlprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
DB01197CaptoprilCaptopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
DB01115NifedipineNifedipine has been formulated as both a long- and short-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nifedipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drug’s vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Nifedipine is used to treat hypertension and chronic stable angina.
DB00457PrazosinPrazosin, also known as _Minipress_, is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988 [L5828]. It belongs to the class of drugs known as alpha-1 antagonists [FDA label], [A176630]. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares [A176618, A176621, A176624].
DrugDrug NameTargetType
DB00770AlprostadilProstaglandin E2 receptor EP2 subtypetarget
DB00770AlprostadilProstaglandin E2 receptor EP1 subtypetarget
DB00770AlprostadilMultidrug resistance-associated protein 5transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 2B1transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 3A1transporter
DB00770AlprostadilMultidrug resistance-associated protein 4transporter
DB00770AlprostadilSolute carrier organic anion transporter family member 2A1transporter
DB00770AlprostadilProstaglandin D2 receptor 2target
DB00770AlprostadilSolute carrier family 22 member 6transporter
DB01197CaptoprilAngiotensin-converting enzymetarget
DB01197CaptoprilCytochrome P450 2D6enzyme
DB01197CaptoprilSerum albumincarrier
DB01197Captopril72 kDa type IV collagenasetarget
DB01197CaptoprilMatrix metalloproteinase-9target
DB01197CaptoprilMultidrug resistance protein 1transporter
DB01197CaptoprilSolute carrier family 15 member 1transporter
DB01197CaptoprilSolute carrier family 22 member 6transporter
DB01197CaptoprilLeukotriene A-4 hydrolasetarget
DB01197CaptoprilB1 bradykinin receptortarget
DB01115NifedipineVoltage-dependent calcium channel subunit alpha-2/delta-1target
DB01115NifedipineCytochrome P450 3A4enzyme
DB01115NifedipineCytochrome P450 2E1enzyme
DB01115NifedipineCytochrome P450 2D6enzyme
DB01115NifedipineCalmodulintarget
DB01115NifedipineVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB01115NifedipineVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB01115NifedipineVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01115NifedipineVoltage-dependent L-type calcium channel subunit beta-2target
DB01115NifedipinePotassium voltage-gated channel subfamily A member 1target
DB01115NifedipineVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB01115NifedipineCytochrome P450 1A2enzyme
DB01115NifedipineCytochrome P450 2A6enzyme
DB01115NifedipineCytochrome P450 2C8enzyme
DB01115NifedipineCytochrome P450 3A5enzyme
DB01115NifedipineCytochrome P450 3A7enzyme
DB01115NifedipineCanalicular multispecific organic anion transporter 2transporter
DB01115NifedipineMultidrug resistance protein 1transporter
DB01115NifedipineCanalicular multispecific organic anion transporter 1transporter
DB01115NifedipineCytochrome P450 1A1enzyme
DB01115NifedipineCytochrome P450 2B6enzyme
DB01115NifedipineNuclear receptor subfamily 1 group I member 2target
DB01115NifedipineSolute carrier organic anion transporter family member 1B1transporter
DB01115NifedipineBile salt export pumptransporter
DB00457PrazosinAlpha-1A adrenergic receptortarget
DB00457PrazosinAlpha-1B adrenergic receptortarget
DB00457PrazosinAlpha-1D adrenergic receptortarget
DB00457PrazosinPotassium voltage-gated channel subfamily H member 2target
DB00457PrazosinAlpha-1-acid glycoprotein 1carrier
DB00457PrazosinSolute carrier family 22 member 1transporter
DB00457PrazosinSolute carrier family 22 member 3transporter
DB00457PrazosinMultidrug resistance protein 1transporter
DB00457PrazosinATP-binding cassette sub-family G member 2transporter
DB00457PrazosinAlpha-2A adrenergic receptortarget
DB00457PrazosinAlpha-2B adrenergic receptortarget
DB00457PrazosinAlpha-1 adrenergic receptorstarget
DrugDrug NamePhaseStatusCount
DB00959Methylprednisolone0Recruiting1
DB00374Treprostinil0Recruiting1
DB00727Nitroglycerin1Completed2
DB00203Sildenafil2 / 3Completed1
DB00203Sildenafil3Completed1
DB00820Tadalafil3Completed1
DB00083Botulinum toxin type A4Recruiting1
DB00770AlprostadilNot AvailableUnknown Status1
DB00559BosentanNot AvailableUnknown Status1